Top

Gepubliceerd in:

2007 | OriginalPaper | Hoofdstuk

Hartfalen: een systemische aandoening

Auteurs : K. van der Putten, R. L. Braam, Dr. C. A. J. M. Gaillard

Uitgeverij: Bohn Stafleu van Loghum

Abstract

Hartfalen wordt in de Multidisciplinaire richtlijn Chronisch hartfalen gedefinieerd als: ‘een complex van klachten en verschijnselen ten gevolge van tekortschietende pompfunctie van het hart’.1 Het tekortschieten van de pompfunctie van het hart leidt ertoe dat het belangrijkste doel van de circulatie, namelijk het waarborgen van een optimale weefseloxygenatie, het aanbieden van nutriënten aan de weefsels en het afvoeren van afvalstoffen, niet wordt bereikt. Het gevolg hiervan is de activatie van hemodynamische en neurohumorale compensatiemechanismen, die aanvankelijk positief werken, maar op termijn een neergaande spiraal vormen. Het zijn dan ook juist deze compensatiemechanismen die in het beloop van hartfalen een belangrijke rol spelen en ook het aangrijpingspunt vormen voor therapie.

vorige hoofdstuk Epidemiologie: prevalentie, incidentie en prognose

volgende hoofdstuk Diagnostiek bij hartfalen

Multidisciplinaire richtlijn Chronisch Hartfalen. Alphen aan den Rijn: Van Zuiden Communications; 2002.

Coats AJ. Heart failure: What causes the symptoms of heart failure? Heart 2001;86(5):574–8.PubMedCrossRef

Ventura-Clapier R, Mettauer B, Bigard X. Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure. Cardiovasc Res 2007;73(1):10–8.PubMedCrossRef

Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001;85(3):342–50.PubMedCrossRef

Cai H, Harrison DG. Endothelial disfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87(10):840–4.PubMedCrossRef

Kojda G, Hambrecht R. Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy? Cardiovasc Res 2005;67(2):187–97.PubMedCrossRef

Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348(20):2007–18.PubMedCrossRef

Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345(18):1291–7.PubMedCrossRef

Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46(6):e1-82.PubMedCrossRef

10.

Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12(1):10–38.

11.

Timmis AD. Diabetic heart disease: clinical considerations. Heart 2001;85(4):463–9.PubMedCrossRef

12.

Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47(4):693–700.PubMedCrossRef

13.

Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005;26(7):650–61.PubMedCrossRef

14.

Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26 (Suppl 1):S80-2.PubMed

15.

Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63(3):1121–9.PubMedCrossRef

16.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296–305.PubMedCrossRef

17.

Varma R, Garrick R, McClung J, Frishman WH. Chronic renal disfunction as an independent risk factor for the development of cardiovascular disease. Cardiol Rev 2005;13(2):98–107.PubMedCrossRef

18.

Hillege HL, Girbes AR, Kam PJ de, Boomsma F, Zeeuw D de, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102(2):203–10.PubMedCrossRef

19.

Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107(2):223–5.PubMedCrossRef

20.

Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2006.

21.

Meer P van der, Lipsic E, Westenbrink BD, Wal RM van de, Schoemaker RG, Vellenga E, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysylproline partially explain the occurrence of anemia in heart failure. Circulation 2005;112(12):1743–7.PubMedCrossRef

22.

Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113(20):2454–61.PubMedCrossRef

23.

Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49(7):753–62.PubMedCrossRef

24.

Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107(2):294–9.PubMedCrossRef

25.

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(5 Suppl 3):S11-145.

26.

Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47.PubMed

27.

Colluci W, Braunwald E. Pathophysiology of heart failure. Chapter 16. In: Braunwald E, Zipes D, Libby P, editors. Heart disease, a textbook of cardiovascular medicine 6th ed. Philadelphia: W.B.Saunders, 2001.

28.

Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101(5):558–69.PubMedCrossRef

29.

Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003;93(10):896–906.PubMedCrossRef

30.

Rochais F, Vilardaga JP, Nikolaev VO, Bunemann M, Lohse MJ, Engelhardt S. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 2007;117(1):229–35.PubMedCentralPubMedCrossRef

31.

Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005;19(1):77–87.PubMedCrossRef

32.

Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69(1):105–13.PubMedCrossRef

33.

Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368(9545):1449–56.PubMedCrossRef

34.

Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001;37(6):1493–505.PubMedCrossRef

35.

Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart 2007;93(1):2–4.PubMedCrossRef

36.

Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46(10):1785–91.PubMedCrossRef

37.

Sulemanjee NZ, Schwarz ER. Conivaptan: a selective vasopressin antagonist. Drugs Today (Barc) 2006;42(6):379–86.CrossRef

38.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319–31.PubMedCrossRef

39.

Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92(6):843–9.PubMedCrossRef

40.

Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343(4):246–53.CrossRef

41.

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356(9230):615–20.PubMedCrossRef

42.

Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, et al. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J 2005;150(2):257–62.PubMedCrossRef

43.

De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362(9380):316–22.PubMedCrossRef

44.

Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107(9):1278–83.PubMedCrossRef

45.

Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323(4):236–41.PubMedCrossRef

46.

Henriksen PA, Newby DE. Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart. Heart 2003;89(1):14–8.PubMedCrossRef

47.

Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broadspectrum anti-inflammatory approaches. Am J Cardiol 2005;95(11A):17C-23C; discussion: 38C-40C.CrossRef

Titel: Hartfalen: een systemische aandoening
Auteurs: K. van der Putten
R. L. Braam
Dr. C. A. J. M. Gaillard
Uitgeverij: Bohn Stafleu van Loghum
Boek: Leerboek hartfalen
Print ISBN: 978-90-313-5022-3

Elektronisch ISBN: 978-90-313-6347-6

Copyright: 2007
DOI: https://doi.org/10.1007/978-90-313-6347-6_3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen